Media Articles Related to Apri (Desogestrel / Estradiol)
Targeted orphaned domain may lead to drug therapies: Research key to possible drug therapies for nervous system diseases and inflammatory processes
Source: Epilepsy News From Medical News Today [2016.05.12]
"Pentameric quaternary structure of the intracellular domain of serotonin type 3A receptors," was published in the April issue of Scientific Reports. Along with her research team, Akash Pandhare, Ph.
New European policy recommendations on cytotoxic drugs
Source: Pharma Industry / Biotech Industry News From Medical News Today [2016.05.03]
New policy recommendations on preventing occupational exposure to cytotoxic drugs were launched in the European Parliament on 26 April 2016, an important new initiative designed to protect...
Contraception Safety Program for Acne Drug Failing in Canada
Source: MedicineNet isotretinoin Specialty [2016.04.26]
Title: Contraception Safety Program for Acne Drug Failing in Canada
Category: Health News
Created: 4/25/2016 12:00:00 AM
Last Editorial Review: 4/26/2016 12:00:00 AM
Published Studies Related to Apri (Desogestrel / Estradiol)
Desogestrel+ethinylestradiol versus levonorgestrel+ethinylestradiol. Which one has better affect on acne, hirsutism, and weight change. [2011.01]
OBJECTIVE: To compare complications of third and second generation oral contraceptive pills (OCPs)... CONCLUSION: In comparison with the LNG+EE OCP, the DSG+EE OCP is a contraceptive pill that significantly decreases the severity of acne and hirsutism, without any significant change in weight.
Route of administration of contraceptives containing desogestrel/etonorgestrel and insulin sensitivity: a prospective randomized study. [2009.07]
BACKGROUND: The study was conducted to investigate whether hormonal contraceptives administered via the oral and vaginal route exert a similar effect on insulin sensitivity (SI)... CONCLUSIONS: The present data indicate that in contrast to OC use, vaginal contraception with the ring does not deteriorate SI. The vaginal ring may represent an appropriate choice for long-term contraception in women at risk for developing diabetes mellitus or metabolic syndrome.
Insulin sensitivity and lipid metabolism with oral contraceptives containing chlormadinone acetate or desogestrel: a randomized trial. [2009.02]
BACKGROUND: Second-generation and third-generation oral contraceptives containing 30 mcg or more of ethinylestradiol (EE) decrease insulin sensitivity (SI). In this study, we investigated whether SI is decreased by contraceptives containing lower doses EE or by progestins with antiandrogenic properties... CONCLUSIONS: The present study confirms that DSG, even when associated with low EE dose, decreases SI. By contrast, EE/CMA does not deteriorate SI and induces a favorable lipid profile.
A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. [2006.04]
PURPOSE: In this open-label, randomized study, we assessed the effects on hemostasis of two combined oral contraceptives containing drospirenone (DRSP) as progestogen component... CONCLUSION: The changes in the hemostatic variables for DRSP/20EE were less pronounced compared to DSG/30EE and DRSP/30EE. The results were in accordance with previous reports on effects of similar OCs.
Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. [2005.06]
OBJECTIVE: To compare the effect of ethinyl estradiol 20 microg/drospirenone 3 mg (EE 20 microg/DRSP 3 mg) administered according to a 24/4 regimen with ethinyl estradiol 20 microg/desogestrel 150 microg (EE 20 microg/DSG 150 microg) administered according to the conventional 21/7 regimen on lipid, carbohydrate and hemostatic parameters... CONCLUSION: EE 20 microg/DRSP 3 mg has a good safety profile comparable with EE 20 microg/DSG 150 microg.
Clinical Trials Related to Apri (Desogestrel / Estradiol)
NuvaRing Versus Marvelon in the Coordination of In Vitro Fertilization Cycles [Terminated]
Presently, a long protocol in an In Vitro Fertilization (IVF) cycle, patients need to take
Marvelon, a drug that inhibits the follicular development at the beginning of the cycle in
order to better control and also plan the onset of the ovary stimulation with gonadotropin.
Marvelon is taken daily as soon as menstruation starts for a period of 14 to 21 days.
Ideally, it has to be taken at the same time everyday and not be forgotten. This may cause
higher stress level for some users. Presently on the market, there is a ring-shaped
contraceptive device inserted in the vagina at day 1 of the cycle called NuvaRing. The
purpose of this device is similar to an oral contraceptive. However, the benefit of NuvaRing
is that it can be left in place for a period of up to 35 days without any other manipulation
and keep an adequate rate of hormone for contraception. Moreover, NuvaRing shows better
hormone stability in the blood. Although the side effects and the benefits are comparable
for the two treatments, some studies have shown that more patients would respect the
treatment with NuvaRing and that the level of satisfaction would be higher in women using
NuvaRing when contraception is needed.
The purpose of the study is to compare the rate of satisfaction as well as the level of
stress in women using Marvelon daily or NuvaRing with single insertion in a long protocol.
Moreover, this study allow us to verify if using NuvaRing, a vaginal contraceptive releasing
constant daily doses for up to 35 days will allow us to facilitate the planning of In Vitro
Fertilization cycles in long protocol.
Post-marketing, Observational Study to Confirm the Safety and Efficacy of MARVELON (Study P06083) [Completed]
The purpose of this study is to evaluate the efficacy and safety of Marvelon® in the
prevention of pregnancy.
Post-marketing surveys are not considered applicable clinical trials and thus the results of
this survey will not be posted at its conclusion. The results will be submitted to public
health officials as required by applicable national and international laws.
New Treatments for Troublesome Bleeding in Implanon Users [Not yet recruiting]
Most Implanon users experience a reduction in the frequency and volume of menstrual
bleeding, but a substantial minority experience unpredictable and frequent and/or prolonged
episodes of bleeding. This is a double blind, placebo controlled, randomised study with an
additional randomised non-blinded arm. Two hundred women between the ages of 18-45 years,
who are Implanon users with prolonged or frequent breakthrough bleeding (WHO definition)
will be recruited and randomised into 4 equal-sized treatment groups of 50 women assigned to
Marvelon 7 days or 21 days, NuvaRing 21 days or placebo. Recruited subjects will maintain a
daily menstrual diary chart for a minimum of 90 days prior to randomisation, and will be
enrolled into the treatment phase provided that they have met one of the World Health
Organization criteria for prolonged or frequent bleeding Following the initial 90 day
record, eligible women will begin designated treatment on day 1 of the next episode of
bleeding or spotting. Analysis of the subsequent menstrual pattern will begin from day 1 of
that bleeding/spotting episode and will continue through 90 days.
A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception [Completed]
The purpose of this study is to evaluate the effectiveness in terms of prevention of
pregnancy and safety of the oral contraceptive Yasmin and Marvelon on cycle control in
healthy Chinese women
Hormonal Contraception and Vaginal Health [Completed]
The purpose of this study is to help determine if the route by which women receive hormonal
contraception causes different changes to occur in the lining of the vagina. The
investigators plan to compare an oral route (taking birth control pills) with a vaginal
route (using a vaginal ring).